vimarsana.com
Home
Live Updates
TAR-200 monotherapy shows greater than 80% complete response
TAR-200 monotherapy shows greater than 80% complete response
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
/PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of...
Related Keywords
United Kingdom ,
United States ,
Texas ,
San Antonio ,
American ,
Ania Diantonio ,
Indianj Urol ,
Joseph Jacob ,
Prnewswire Johnson ,
Clin Urol ,
Janssen Research Development ,
American Cancer Society ,
European Association Of Urology ,
European Society For Medical Oncology ,
Bladder Cancer Advocacy Network ,
Drug Administration ,
None Of Janssen Research Development ,
Exchange Commission ,
American Urological Association Annual Meeting ,
Johnson ,
Janssen Biotech Inc ,
Department Of Urology ,
Bacillus Calmette Gu ,
Urological Association Annual Meeting ,
Upstate Medical University ,
European Society ,
Medical Oncology ,
European Association ,
Christopher Cutie ,
Vice President ,
Disease Area Leader ,
Bladder Cancer ,
Johnson Innovative ,
Therapy Designation ,
Janssen Oncology ,
High Risk Non ,
Muscle Invasive Bladder Cancer ,
Innovative Medicine ,
Janssen Research ,
Janssen Biotech ,
Private Securities Litigation Reform Act ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Accessed April ,
Urol Assoc ,
Bladder Cancer Advocacy ,